BR112013017722A2 - combinação - Google Patents

combinação

Info

Publication number
BR112013017722A2
BR112013017722A2 BR112013017722A BR112013017722A BR112013017722A2 BR 112013017722 A2 BR112013017722 A2 BR 112013017722A2 BR 112013017722 A BR112013017722 A BR 112013017722A BR 112013017722 A BR112013017722 A BR 112013017722A BR 112013017722 A2 BR112013017722 A2 BR 112013017722A2
Authority
BR
Brazil
Prior art keywords
chloro
human
treatment
treating cancer
relates
Prior art date
Application number
BR112013017722A
Other languages
English (en)
Inventor
Rakesh Kumar
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112013017722A2 publication Critical patent/BR112013017722A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

combinação a presente invenção refere-se a um método de tratamento do câncer num ser humano e combinações farmacêuticas úteis em tal tratamento. em particular, o método está relacionado a um método de tratamento do câncer que inclui a administração de um composto inibidor da proteassoma, e n-{(1s)-2-amino-1-[)3-fluorfenil)-metil]-etil}-5-cloro-4- (4-cloro-1-mentil-1h-pirazol-5-il)-2-tiofenocarboxamida, ou um seu sal famaceuticamente aceitável; e opcionais agentes antineoplásticos adicionais, a um ser humano com necessidade desse tratamento.
BR112013017722A 2011-01-11 2012-01-11 combinação BR112013017722A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431508P 2011-01-11 2011-01-11
PCT/US2012/020863 WO2012097021A1 (en) 2011-01-11 2012-01-11 Combination

Publications (1)

Publication Number Publication Date
BR112013017722A2 true BR112013017722A2 (pt) 2016-07-12

Family

ID=46507420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013017722A BR112013017722A2 (pt) 2011-01-11 2012-01-11 combinação

Country Status (15)

Country Link
US (6) US20130288984A1 (pt)
EP (1) EP2663189B1 (pt)
JP (1) JP6100700B2 (pt)
KR (1) KR20140053836A (pt)
CN (1) CN103298345B (pt)
AU (1) AU2012205601B2 (pt)
BR (1) BR112013017722A2 (pt)
CA (1) CA2824201A1 (pt)
EA (1) EA029000B1 (pt)
ES (1) ES2689760T3 (pt)
IL (1) IL227097B (pt)
MX (1) MX356704B (pt)
SG (2) SG10201600077RA (pt)
WO (1) WO2012097021A1 (pt)
ZA (1) ZA201304139B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105792825A (zh) * 2013-10-01 2016-07-20 诺华股份有限公司 组合
KR20160070188A (ko) * 2013-11-07 2016-06-17 데시페라 파마슈티칼스, 엘엘씨. 암치료에 유용한 tie2 키나아제의 억제 방법
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
BR112022013169A2 (pt) 2019-12-30 2022-09-13 Deciphera Pharmaceuticals Llc Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea
RS65058B1 (sr) 2019-12-30 2024-02-29 Deciphera Pharmaceuticals Llc Formulacije inhibitora amorfne kinaze i postupci njihove primene
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6328590B1 (en) 2000-07-20 2001-12-11 Emc Corporation Methods and apparatus for controlling attachment of an electronic module with a circuit board connector
EP1740579B1 (en) * 2004-03-24 2015-08-19 AbbVie Inc. Tricyclic pyrazole kinase inhibitors
EP2708531A1 (en) 2004-10-13 2014-03-19 Pharmacia & Upjohn Company LLC Crystalline Forms Of 3-[5-Chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
JP2009506069A (ja) * 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP1840114A1 (en) 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
JP2009532497A (ja) 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
WO2007122686A1 (ja) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
CN104306977A (zh) 2006-08-25 2015-01-28 库伽尔生物科技公司 治疗癌症的方法和组合物
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
JP4299327B2 (ja) 2006-08-31 2009-07-22 トヨタ自動車株式会社 可変バルブタイミング装置
US8828451B2 (en) 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
CN101535278B (zh) 2006-10-13 2011-12-28 巴斯夫欧洲公司 2-氯-5-[3,6-二氢-3-甲基-2,6-二氧代-4-(三氟甲基)-1-(2h)嘧啶基]-4-氟-n-[[甲基(1-甲基乙基)氨基]磺酰基]苯甲酰胺的水合物
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
MY150059A (en) 2007-10-11 2013-11-29 Astrazeneca Ab Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
DE102008044901A1 (de) 2008-08-29 2010-03-04 Siemens Aktiengesellschaft Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage
SG172926A1 (en) 2009-01-30 2011-08-29 Glaxosmithkline Llc Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
MY155570A (en) 2009-06-26 2015-10-30 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
EA023018B1 (ru) 2009-10-08 2016-04-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинация для лечения рака или предраковых синдромов
CN103874689B (zh) 2011-04-01 2016-04-27 基因泰克公司 Akt抑制剂化合物和威罗菲尼的组合及使用方法
CA2834850A1 (en) 2011-05-03 2012-11-08 University Of Rochester Methods for treating prostate cancer
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
PL2766381T3 (pl) 2011-10-10 2016-12-30 Sposób wytwarzania steroidów podstawionych w pozycji 17
WO2013079964A1 (en) 2011-11-30 2013-06-06 Astrazeneca Ab Combination treatment of cancer
UA114421C2 (uk) 2012-06-04 2017-06-12 Фармасайклікс Ллс Кристалічна форма інгібітору тирозинкінази брутона
MX2016004265A (es) 2013-10-01 2016-07-08 Novartis Ag Combinacion.

Also Published As

Publication number Publication date
KR20140053836A (ko) 2014-05-08
JP2014507412A (ja) 2014-03-27
US20170100449A1 (en) 2017-04-13
MX2013008074A (es) 2013-08-09
JP6100700B2 (ja) 2017-03-22
EA029000B1 (ru) 2018-01-31
AU2012205601A1 (en) 2013-08-01
US20160022641A1 (en) 2016-01-28
MX356704B (es) 2018-06-11
CA2824201A1 (en) 2012-07-19
EP2663189A1 (en) 2013-11-20
ES2689760T3 (es) 2018-11-15
WO2012097021A1 (en) 2012-07-19
SG191724A1 (en) 2013-08-30
IL227097B (en) 2018-02-28
EP2663189A4 (en) 2014-06-11
SG10201600077RA (en) 2016-02-26
US20130288984A1 (en) 2013-10-31
US20160375086A1 (en) 2016-12-29
US20120258933A1 (en) 2012-10-11
EA201391027A1 (ru) 2014-01-30
US20150119337A1 (en) 2015-04-30
CN103298345A (zh) 2013-09-11
EP2663189B1 (en) 2018-07-04
ZA201304139B (en) 2014-02-26
CN103298345B (zh) 2016-12-14
US10449226B2 (en) 2019-10-22
AU2012205601B2 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
BR112013017722A2 (pt) combinação
PH12016502355B1 (en) Pharmaceutical composition
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
BR112014026493A2 (pt) derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
BR112014016163A2 (pt) piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
BR112014025711A2 (pt) composto, medicamento, e, uso de um composto
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2014003180A (es) Metodos para tratar vhc.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
BR112012022243A2 (pt) terapias inibidoras de autografia baseadas em tioxantona para tratar câncer
MX2019009630A (es) Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion.
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
BR112015030623A2 (pt) agentes citotóxicos para o tratamento de câncer
BR112017001165A2 (pt) terapia combinada

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVARTIS PHARMA AG (CH)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2548 DE 05-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.